Literature DB >> 10411505

Prevention of graft versus host disease by inactivation of host antigen-presenting cells.

W D Shlomchik1, M S Couzens, C B Tang, J McNiff, M E Robert, J Liu, M J Shlomchik, S G Emerson.   

Abstract

Graft versus host disease, an alloimmune attack on host tissues mounted by donor T cells, is the most important toxicity of allogeneic bone marrow transplantation. The mechanism by which allogeneic T cells are initially stimulated is unknown. In a murine allogeneic bone marrow transplantation model it was found that, despite the presence of numerous donor antigen-presenting cells, only host-derived antigen-presenting cells initiated graft versus host disease. Thus, strategies for preventing graft versus host disease could be developed that are based on inactivating host antigen-presenting cells. Such strategies could expand the safety and application of allogeneic bone marrow transplantation in treatment of common genetic and neoplastic diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411505     DOI: 10.1126/science.285.5426.412

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  338 in total

1.  Immunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets.

Authors:  Kenichirou Tajima; Ryuichi Amakawa; Tomoki Ito; Michihiko Miyaji; Masashi Takebayashi; Shirou Fukuhara
Journal:  Immunology       Date:  2003-03       Impact factor: 7.397

2.  Reduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1/Th17 differentiation.

Authors:  Qing Ma; Dan Li; Roza Nurieva; Rebecca Patenia; Roland Bassett; Wei Cao; Andrei M Alekseev; Hong He; Jeffrey J Molldrem; Michael H Kroll; Richard E Champlin; George E Sale; Vahid Afshar-Kharghan
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-01       Impact factor: 5.742

3.  Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.

Authors:  Shoji Asakura; Daigo Hashimoto; Shuichiro Takashima; Haruko Sugiyama; Yoshinobu Maeda; Koichi Akashi; Mitsune Tanimoto; Takanori Teshima
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

Review 4.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

5.  Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease.

Authors:  Erin Gatza; Daniel R Wahl; Anthony W Opipari; Thomas B Sundberg; Pavan Reddy; Chen Liu; Gary D Glick; James L M Ferrara
Journal:  Sci Transl Med       Date:  2011-01-26       Impact factor: 17.956

Review 6.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Authors:  Elizabeth O Stenger; Hēth R Turnquist; Markus Y Mapara; Angus W Thomson
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

7.  Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells.

Authors:  Tomomi Toubai; Isao Tawara; Yaping Sun; Chen Liu; Evelyn Nieves; Rebecca Evers; Thea Friedman; Robert Korngold; Pavan Reddy
Journal:  Blood       Date:  2011-11-18       Impact factor: 22.113

8.  Siglec-G represses DAMP-mediated effects on T cells.

Authors:  Tomomi Toubai; Corinne Rossi; Katherine Oravecz-Wilson; Cynthia Zajac; Chen Liu; Thomas Braun; Hideaki Fujiwara; Julia Wu; Yaping Sun; Stuart Brabbs; Hiroya Tamaki; John Magenau; Pang Zheng; Yang Liu; Pavan Reddy
Journal:  JCI Insight       Date:  2017-07-20

Review 9.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

10.  Emergent autoimmunity in graft-versus-host disease.

Authors:  Elizabeth Tivol; Richard Komorowski; William R Drobyski
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.